Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew R. Balmforth has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cholera Toxin-Mediated Targeting of Botulinum Neurotoxin Activity to Pain-Associated Sensory Neurons

    by Eve Corrie, Rebecca Bresnahan, Ciara Doran, Charlotte Leese, Matthew R. Balmforth, Anna Andreou, Aisha Zhantleuova, Elizabeth P. Seward, Michael E. Webb, W. Bruce Turnbull, et al.

    Botulinum neurotoxin injections are used off-label to treat chronic pain, but their efficacy is limited and paralytic effects restrict clinical utility in these applications. Here, we investigated whether combining the light chain and translocation domains of botulinum neurotoxin A (BoNT/A) with the GM1-binding B subunit of cholera toxin would be beneficial in silencing pain-associated sensory neurons. Chimeric ChoBot was assembled via a coiled-coil linking technology and was shown to retain the enzymatic activity of BoNT/A in vitro and in vivo. In cultured dorsal root ganglion neurons, ChoBot cleaved SNAP25 in a calcitonin gene-related peptide (CGRP)-rich subpopulation of sensory neurons, resulting in marked inhibition of CGRP release. ChoBot had a lesser effect on the compound muscle action potentials of the rat gastrocnemius muscle than BoNT/A following subcutaneous injections. In rat models of pain, including chemotherapy-induced peripheral neuropathy, intraplantar administration of ChoBot significantly attenuated mechanical allodynia. Immunohistochemical analysis confirmed SNAP25 cleavage in NF200- and CGRP-expressing sensory fibres in the epidermis following a single injection. ChoBot also mediated SNAP25 cleavage in human neuroblastoma cells in culture. Together, these findings indicate that ChoBot enables a silencing of pain-associated sensory pathways, providing a new strategy for the development of new long-lasting analgesics for chronic pain.

  • Open Access

    Discovery and chemical optimisation of a potent, Bi-cyclic antimicrobial inhibitor of Escherichia coli PBP3

    by Catherine E. Rowland, Hector Newman, Tazmin T. Martin, Rachel Dods, Nikolaos Bournakas, James M. Wagstaff, Nick Lewis, Steven J. Stanway, Matthew Balmforth, Celia Kessler, et al.

    Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of bicyclic peptide (Bicycle®) inhibitors of E. coli PBP3 (EcPBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent, to our knowledge, a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors. This work demonstrates an approach to rapidly find binders to antimicrobial targets, combined with an entry mechanism to provide access to the Gram negative cell.


  • Open Access

    Synthesis and screening of a library of Lewisx deoxyfluoro-analogues reveals differential recognition by glycan-binding partners

    by Kristian Hollingsworth, Antonio Di Maio, Sarah-Jane Richards, Jean-Baptiste Vendeville, David E. Wheatley, Claire E. Council, Tessa Keenan, Hélène Ledru, Harriet Chidwick, Kun Huang, et al.

    Glycan-mediated interactions play a crucial role in biology and medicine, influencing signalling, immune responses, and disease pathogenesis. However, the use of glycans in biosensing and diagnostics is limited by cross-reactivity, as certain glycan motifs can be recognised by multiple biologically distinct protein receptors. To address this specificity challenge, we report the enzymatic synthesis of a 150-member library of site-specifically fluorinated Lewisx analogues (‘glycofluoroforms’) using naturally occurring enzymes and fluorinated monosaccharides. Subsequent incorporation of a subset of these glycans into nanoparticles or a microarray revealed a striking spectrum of distinct binding intensities across different proteins that recognise Lewisx. Notably, we show that for two proteins with unique binding sites for Lewisx, glycofluoroforms exhibited enhanced binding to one protein, whilst reduced binding to the other, with selectivity governed by fluorination patterns. We finally showcase the potential diagnostic utility of this approach in glycofluoroform-mediated bacterial toxin detection by lateral flow.


  • Open Access

    Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle ® ) Antimicrobial Inhibitor of Escherichia coli PBP3

    by Catherine E. Rowland, Hector Newman, Tazmin T. Martin, Rachel Dods, Nikolaos Bournakas, James M. Wagstaff, Nick Lewis, Steven J. Stanway, Matthew Balmforth, Celia Kessler, et al.

    Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of novel, bicyclic peptide (Bicycle ® ) inhibitors of E. coli PBP3 ( Ec PBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors.


  • Open Access

    Rapid discovery of high-affinity antibodies via massively parallel sequencing, ribosome display and affinity screening

    by Benjamin T. Porebski, Matthew Balmforth, Gareth Browne, Aidan Riley, Kiarash Jamali, Maximillian J. L. J. Fürst, Mirko Velic, Andrew Buchanan, Ralph Minter, Tristan Vaughan, et al.

    Developing therapeutic antibodies is laborious and costly. Here we report a method for antibody discovery that leverages the Illumina HiSeq platform to, within 3 days, screen in the order of 10 8 antibody–antigen interactions. The method, which we named ‘deep screening’, involves the clustering and sequencing of antibody libraries, the conversion of the DNA clusters into complementary RNA clusters covalently linked to the instrument’s flow-cell surface on the same location, the in situ translation of the clusters into antibodies tethered via ribosome display, and their screening via fluorescently labelled antigens. By using deep screening, we discovered low-nanomolar nanobodies to a model antigen using 4 × 10 6 unique variants from yeast-display-enriched libraries, and high-picomolar single-chain antibody fragment leads for human interleukin-7 directly from unselected synthetic repertoires. We also leveraged deep screening of a library of 2.4 × 10 5 sequences of the third complementarity-determining region of the heavy chain of an anti-human epidermal growth factor receptor 2 (HER2) antibody as input for a large language model that generated new single-chain antibody fragment sequences with higher affinity for HER2 than those in the original library.


  • Open Access

    A ‘glyco-fluorine’ code revealing differential recognition by glycan binding partners

    by Kristian Hollingsworth, Antonio Di Maio, Sarah-Jane Richards, Jean-Baptiste Vendeville, David E. Wheatley, Claire E. Council, Tessa Keenan, Helene Ledru, Harriet Chidwick, Huang Kun, et al.

    Biosensing or diagnostics using glycan sequences as targets is limited by glycan cross-reactivities. As binding sites of different proteins that all recognise a given glycan will not be identical, we introduce application of a library of synthetic analogues of a single glycan ligand as a powerful approach to obtain fingerprint binding profiles. We report the enzymatic synthesis of a 150-member library of fluorinated Lewisx analogues (‘glycofluoroforms’) using naturally occurring enzymes and fluorinated monosaccharide building blocks, and the incorporation of a subset into lipid-linked glycan probes or into glyconanoparticles for probing protein binding both in solid-phase high-throughput glycan microarray screening analyses and in solution-phase nanoparticle-based interaction studies. These fluorinated Lewisx analogues, which NMR studies showed to have very similar 3D structures compared to the nonfluorinated Lewisx, gave variously increased or decreased binding with a set of proteins, the different proteins having different preferences and tolerances for binding.

  • Open Access

    Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

    by Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, et al.

    Background: Serum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments described to date and versatile tools for protein engineering.Methods: Here, we used phage display of bovine immune material to derive knob domains against human and rodent serum albumins. These were used to engineer bispecific Fab fragments, by using the framework III loop as a site for knob domain insertion. Results: By this route, neutralisation of the canonical antigen (TNFα) was retained but extended pharmacokinetics in-vivo were achieved through albumin binding. Structural characterisation revealed correct folding of the knob domain and identified broadly common but non-cross-reactive epitopes. Additionally, we show that these albumin binding knob domains can be chemically synthesised to achieve dual IL-17A neutralisation and albumin binding in a single chemical entity. Conclusions: This study enables antibody and chemical engineering from bovine immune material, via an accessible discovery platform.


  • Piggybacking on the Cholera Toxin: Identification of a CTB-Binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons

    by Matthew R. Balmforth, Jessica Haigh, Vajinder Kumar, Wenyue Dai, Christian Tiede, Darren C. Tomlinson, Jim Deuchars, Michael E. Webb, W. Bruce Turnbull

    A significant unmet need exists for the delivery of biologic drugs such as polypeptides or nucleic acids to the central nervous system for the treatment and understanding of neurodegenerative diseases. Naturally occurring bacterial toxins have been considered as tools to meet this need. However, due to the complexity of tethering macromolecular drugs to toxins and the inherent dangers of working with large quantities of recombinant toxins, no such route has been successfully exploited. Developing a method where a bacterial toxin’s nontoxic targeting subunit can be assembled with a drug immediately prior to in vivo administration has the potential to circumvent some of these issues. Using a phage-display screen, we identified two antibody mimetics, anticholera toxin Affimer (ACTA)-A2 and ACTA-C6 that noncovalently associate with the nonbinding face of the cholera toxin B-subunit. In a first step toward the development of a nonviral motor neuron drug-delivery vehicle, we show that Affimers can be selectively delivered to motor neurons in vivo.


  • An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics

    by James M. Wagstaff, Matthew Balmforth, Nicholas Lewis, Rachel Dods, Catherine Rowland, Katerine van Rietschoten, Liuhong Chen, Helen Harrison, Michael J. Skynner, Michael Dawson, et al.

    Treating infection by Gram-negative bacteria is increasingly challenging as resistance to existing antibiotics spreads. Constrained peptides, selected for high target specificity and affinity via library display technologies, are an emerging therapeutic modality in many disease areas and may be a fertile source of new antibiotics. Currently, the utility of constrained peptides and other large molecules as antibiotics is limited by the outer membrane (OM) barrier of Gram-negative bacteria. However, adding certain moieties to large molecules can confer the ability to cross the OM – these moieties function as intramolecular trans-OM “vectors”. Here, we present a method to systematically assess the carrying capacity of candidate trans-OM vectors using a real-time luminescence assay (“SLALOM”), reporting on periplasmic entry. We demonstrate the usefulness of our tools by constructing a 3800 Da chimeric compound comprised of a constrained bicyclic peptide (Bicycle®), with a periplasmic target, linked to an intramolecular peptide vector, the resulting chimera is a broad-spectrum inhibitor of pathogenic Gram-negative bacterial growth.


  • Open Access

    Piggybacking on the Cholera Toxin: Identification of a Toxoid-binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons

    by Matthew R. Balmforth, Jessica Haigh, Christian Tiede, Darren C. Tomlinson, Jim Deuchars, Michael E. Webb, W. Bruce Turnbull

    A significant unmet need exists for the delivery of biologic drugs such as polypeptides or nucleic acids, to the central nervous system (CNS) for the treatment and understanding of neurodegenerative diseases. Naturally occurring toxoids have been considered as tools to meet this need. However, due to the complexity of tethering macromolecular drugs to toxins, and the inherent dangers of working with large quantities of recombinant toxin, no such route has been successfully exploited. Developing a method where toxoid and drug can be assembled immediately prior to in vivo administration has the potential to circumvent some of these issues. Using a phage-display screen, we identified two antibody mimetics, Anti-Cholera Toxoid Affimer (ACTA) -A2 and ACTA-C6 that non-covalently associate with the non-binding face of the cholera toxin B-subunit. In a first step toward the development of a non-viral motor neuron drug-delivery vehicle, we show that Affimers can be selectively delivered to motor neurons in vivo .